drugset / Trial / NCT00098345

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

NCT00098345

Phase 2 Completed 40 enrolled Genzyme, a Sanofi Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.

Timeline

Start
2004-11
Primary completion
2008-02
Completion
2017-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule 300 mg Oral

Indications